Indeed, reducing cellular Gln levels during Gln withdrawal [75], GLS knockdown, or exposure of cells to the GLS inhibitor CB-839 all resulted in a robust induction of ROS in high GLS-expressing but not in low GLS-expressing ovarian cancer cells [76], further supporting the roles of GLS in ROS production. The gene discussed is GLS; the disease is ovarian carcinoma.